Moorestown, New Jersey, United States

7322321334

seeking biotech alpha

investments of dan watson as of 5/24/2019

image115
image116

BIOTECH WAR$ 4

May 24, 2019 11:56 AM ET|About: (CELG), JNJ, LLY, MRK, NVS, ABBV, ARRY, MDT, PFE

 Summary

the BIOTECH WAR$ have expanded to include a new and unexpected target, “wealthy people”.


the victorious party wants to remove all undesirable citizens/unlikely supporters from the state in which they live. Acrimony against biotech companies and now wealthy citizens is where we are at.


Biotech companies are an insufficient sector to the politico’s, and a more expansive “Bad Guy Group” is now needed – i.e., wealthy people, especially if you live in NJ.

BIOTECH WAR$ 4

 danwatson888's Blog

long only, Deep Value, dividend growth investing, healthcare

BIOTECH WAR$ 4
image117

BIOTECH WAR$™ III

May 9, 2019 8:52 AM ET|About: Johnson & Johnson (JNJ), MRK

Summary


the BIOTECH WAR$ may represent a deeper battle going on between the “Socialist” political movement and our current “Capitalistic” economy.


Achieving political power supersedes common sense and support for the biotech business sector becomes non-existent as the sector is politically vilified.


Positive biotech product news seems to have little effect towards improving market valuations.

danwatson888's Blog, long only, Deep Value, dividend growth investing, healthcare

 The BIOTECH WAR$ continue in 2019 and the people, mostly politicians, who put down, attack and denigrate the entire biotech sector, are currently “Wining” the BIOTECH WAR$. These people “target” the biotech sector as much as they can, as it is a sure way to appeal to the voting public, win votes and win elections.  

BIOTECH WAR$™ III
image118

the Biotech Wars continue

Summary

 

The “Medicare for all” and the “drug pricing” messaging is working for all those who seek political gain.


Biotech, Medtech and the entire Healthcare sector are losing the battles, and the war as investors flee for less politically targeted sectors.


NJ residents see the "P/C", "Middle Class Only"/ Socialism wave coming.


I may need to stop being so publicly supportive of Biotech companies.

BIOTECH WAR$ II™

 For now I will remain publicly supportive of all my biotech investments, but this situation may change as I continue to see the "P/C" movement/"Middle Class Only"/ Socialism movement accelerate.  

BIOTECH WAR$ II™

blogs from dan watson / danwatson888's Blog

My Blog

seeking biotech alpha October 2018 insight

image186

 OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression Over Five Years in Relapsing and Primary Progressive Multiple Sclerosis

Wed October 10, 2018 1:00 AM|Business Wire|About: RHHBY 

OCREVUS is a prescription medicine used to treat adults with relapsing or primary progressive forms of multiple sclerosis.
image187

 EAST HANOVER, N.J., Oct. 9, 2018 /PRNewswire/  

Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study

 NVS 

Crizanlizumab is a monoclonal antibody developed by Novartis targeted towards P-selectin. It was announced by the company as an effective drug to prevent vaso-occlusive crisis in patients with Sickle cell anemia.
image188

 New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018

Wed October 10, 2018 7:30 AM|Business Wire|About: CELG 

Ozanimod (RPC-1063) is an investigational therapy being developed by Celgene to treat ulcerative colitis (UC), a form of inflammatory bowel disease (IBD).
image189

 Incyte Announces Data for Pemigatinib, its Selective FGFR Inhibitor, to be Featured at the ESMO 2018 Congress

Tue October 9, 2018 7:30 AM|Business Wire|About: INCY 

nterim Phase 2 results highlight the potential of pemigatinib (INCB54828) in cholangiocarcinoma and urothelial carcinoma October 09, 2018 07:30 AM Eastern Daylight Time
image190

 BeiGene Announces National Reimbursement Inclusion of VIDAZA® (Azacitidine for Injection) by the State Medical Insurance Administration in China

Wed October 10, 2018 6:00 AM|GlobeNewswire|About: BGNE 

image191

 New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Wed October 10, 2018 6:30 AM|PR Newswire|About: LLY 

JARDIANCE is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.

seeking biotech alpha October 2018 insight

image192

  Novartis to Launch Innovation Labs Across the Globe, Including Silicon Valley

Published: Oct 09, 2018 By Alex Keown

  2018 BioSpace.com.  

image193

 Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed 

 SAN FRANCISCO, OCTOBER 3, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson unveils new 96-week data for SYMTUZA (darunavir 200 mg, cobicistat 150 mg, emtricitabine 200mg, and tenofovir alafenamide 10 mg; D/C/F/TAF),  Adults with HIV-1 

SYMTUZA™ is a prescription medicine that is used without other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults
image194

 Merck snags national VA contract for its Remicade biosimilar thanks to discount pricing offer

by Eric Sagonowsky | Oct 8, 2018 11:12am  


Merck has a biosimilars partnership with South Korea's Samsung Bioepis. (Merck)

Merck’s Renflexis hasn’t made much of a splash on the market since its FDA approval last April, but the company has now won business with the Department of Veterans Affairs thanks to a pricing offer that beat out its rivals.

RENFLEXIS is biosimilar to Remicade® (infliximab). A biosimilar is a medicine approved by the Food and Drug Administration (FDA) as being highly similar to an already approved biologic medicine. The FDA refers to the already approved biologic as the reference product. It is also known as the originator biologic product. There are no clinically meaningful differences in effectiveness and safety between RENFLEXIS and Remicade. That’s one of the reasons why doctors prescribe RENFLEXIS.
image195

 Novartis Looks To Maintain Market Strength In Multiple Sclerosis Space

 
Oct. 9, 2018 11:22 AM ET  | About: Novartis AG (NVS), Includes: BIIB, CELG 

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
image197

 Janssen Announces Exclusive, Worldwide License Agreement with Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection 

 TITUSVILLE, N.J., October 4, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Janssen Pharmaceuticals, Inc., (Janssen) has entered into an agreement with Arrowhead Pharmaceuticals, Inc., (Arrowhead) for an exclusive, worldwide license to develop and commercialize ARO-HBV, a Phase 1/2 subcutaneous, ribonucleic acid interference (RNAi) therapy candidate being investigated for the treatment of chronic hepatitis B viral infection. 

seeking biotech alpha October 2018 insight

image199

 Lilly to Present New Data From Oncology Portfolio at ESMO 2018 Congress, Showcasing Patient-Centric Advances in Cancer Care

Mon October 8, 2018 6:05 PM|PR Newswire|About: LLY 

Lilly Oncology
image200

 Merck’s Broad Oncology Pipeline to Be Highlighted at ESMO 2018 Congress

Tue October 9, 2018 6:30 AM|Business Wire|About: MRK 

ONCOLOGY PRODUCTS & PRESCRIBING INFORMATION
image202

 Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Program and across a Wide Range of Cancers at the European Society for Medical Oncology (ESMO) 2018 Congress

Tue October 9, 2018 1:00 AM|Business Wire|About: RHHBY 

Roche - Cancer immunotherapy For more than 50 years, Roche has been developing medicines with the goal to redefine treatment in oncology. Today, we’re investing more than ever to bring personalised immunotherapy to people with cancer.
image203

 BeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical Meetings

Mon October 8, 2018 6:05 PM|GlobeNewswire|About: BGNE 

CANCER BIOLOGY PLATFORM

seeking biotech alpha October 2018 insight

image204

 INDIANAPOLIS, Oct. 4, 2018 /PRNewswire/   

Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes

Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
image205

Thu October 4, 2018 6:45 AM|Business Wire|About: MRK

 Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens


Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate)
image206

 Health Canada OKs AbbVie's elagolix for endometriosis-related pain

Oct. 6, 2018 2:20 PM ET|About: AbbVie Inc. (ABBV)|By: , SA News Editor  

ORILISSA™ (elagolix) is indicated for the management of moderate to severe pain associated with endometriosis.
image207

 Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Wed October 3, 2018 8:30 AM|Business Wire|About: GILD

– Biktarvy Showed High Efficacy and a Demonstrated Tolerability Profile Through 96 Weeks –

BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in adults.
image208

 New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy

Sat October 6, 2018 7:30 AM|GlobeNewswire|About: BIIB 

SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.
image209

 FDA OKs expanded use for Merck's Gardasil 9 HPV vaccine

Oct. 5, 2018 4:58 PM ET|About: Merck & Co Inc. (MRK)|By: , SA News Editor 

Gardasil 9 HPV vaccine

seeking biotech alpha September 2018 insight

image210

 Thu September 27, 2018 7:52 PM|PR Newswire|About: LLY

INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY

Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults

by Eric Sagonowsky | Sep 27, 2018 8:10pm Lilly’s Emgality nabs third-to-market migraine nod, but aims to be 'treatment of choice' in CGRP
image211

  Thu September 27, 2018 5:41 PM|Business Wire|About: PFE 

 NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE

U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

U.S. FDA APPROVES VIZIMPRO® (DACOMITINIB)
image212

 by Nick Paul Taylor

Sep 28, 2018 7:33am

 Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T cells (Tregs) in preclinical tests 

Tusk Therapeutics is a privately-held, immuno-oncology company, focused on discovering and developing unique therapeutic antibodies that harness the power of the immune system for the treatment of cancer. ​
image213

  Sep. 28, 2018 7:07 AM ET|About: Novo Nordisk A/S (NVO)|By: , SA News Editor 

Novo's once-weekly somapacitan on par with daily Norditropin in mid-stage study

NVO R&D Pipeline
image214

 Thursday, September 20, 2018 - 8:00amEDT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE)

 PFIZER GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR THE PREVENTION OF INVASIVE DISEASE AND PNEUMONIA IN ADULTS AGED 18 YEARS AND OLDER

image215

 SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)  

Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product 


 Novartis (NYSE:NVS) unit Sandoz will commercialize. 

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a specialty biopharmaceutical company focused on developing and commercializing pharmaceutical products in the therapeutic areas of respiratory disease and allergy.

seeking biotech alpha September 2018 insight

image216

  Sep. 25, 2018 9:57 AM ET|About: AstraZeneca Group plc (AZN)|By: , SA News Editor 

 AstraZeneca's Imfinzi improved survival in late-stage lung cancer study

IMFINZI® (durvalumab) is a prescription medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC).
image217

 Sep. 24, 2018 1:29 PM ET|By: , SA News Editor  

 Abiomed (ABMD +8.1%) is up average volume on the heels of its announcement of results from a new analysis of real-world data from its Impella Quality Database that showed a relative increase of 24% in average survival in acute myocardial infarction cardiogenic shock patients since Impella's U.S. approval for cardiogenic shock. 

Impella® The World's Smallest Heart Pump
image218

 Sep. 24, 2018 1:24 PM ET

About: Abbott Laboratories (ABT)  

  

Abbott: MitraClip Success Provides Upside For Stock

Abbott's MitraClip® is Superior to Medical Therapy
image219

  September 24, 2018 07:00 AM EDT 

FARXIGA Achieved a Positive Result in the Phase III DECLARE-TIMI 58 Trial, a Large Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes


FARXIGA is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
image220

 Sep. 24, 2018 11:27 AM ET|About: AstraZeneca Group plc (AZN)|By: , SA News Editor 

 AstraZeneca's Imfinzi OK'd in Europe for advanced lung cancer

Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer
image221

 TOKYO and CHERTSEY, England, Sept. 24, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)   

Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

XTANDI is a prescription medicine used to treat men with prostate cancer that no longer responds to a medical or surgical treatment that lowers testosterone.

seeking biotech alpha September 2018 insight

image222

 Sep. 18, 2018 8:24 AM ET|About: AstraZeneca Group plc (AZN)|By: , SA News Editor   

AstraZeneca's FASENRA shows safety and sustained efficacy in long-term phase III BORA trial in severe eosinophilic asthma

FASENRA IS DESIGNED TO WORK WITH THE BODY TO HELP REMOVE EOSINOPHILS, A KEY CAUSE OF SEVERE ASTHMA.
image223

  September 18, 2018 06:59 AM EDT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY

European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma

EMPLICITI™ (elotuzumab) is a prescription medicine used to treat multiple myeloma in combination with the medicines REVLIMID® (lenalidomide) and dexamethasone in people who have received one to three prior treatments for their multiple myeloma.
image224

   Sep. 18, 2018 7:22 AM ET|By: , SA News Editor  

The European Medicines Agency (EMA) accepts for review Bristol-Myers Squibb's (NYSE:BMY) marketing application seeking approval for EMPLICITI (elotuzumab), in combination with Celgene's (NASDAQ:CELG) POMALYST (pomalidomide) and low-dose dexamethasone, for the treatment of adult patients with multiple myeloma (MM) 


POMALYST is a prescription medicine, taken along with the medicine dexamethasone, used to treat people with multiple myeloma who have previously received at least 2 medicines to treat multiple myeloma, including a proteasome inhibitor and lenalidomide, and whose disease has become worse during treatment or within 60 days of finishing the last treatment.
image225

 DUBLIN - September 18, 2018 - Medtronic plc (NYSE:MDT)  

(GLOBE NEWSWIRE via COMTEX) --Medtronic Receives FDA Approval for Revised TAVR Labeling and Begins Investigational Study of Low Risk Patients with Bicuspid Valves 

The Evolut™ PRO System combines exceptional valve design and advanced sealing with an excellent safety profile.
image227

 Mon September 24, 2018 9:00 PM|PR Newswire|About: AMGN 

 BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia

BLINCYTO® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy.

seeking biotech alpha September 2018 insight

image228

Sep. 14, 2018 4:50 PM ET  | About: Roche Holding Ltd ADR (RHHBY), RHHBF 

Roche Holding's (RHHBY) Virtual Late Stage Pipeline Event 2018 - Slideshow


image229

 Sat September 15, 2018 2:00 AM|Business Wire|About: PFE

NEW YORK--(BUSINESS WIRE)-- 

Pfizer Inc. (PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, 

image230

  by john carroll — on September 14, 2018 08:37 AM EDT 

 According to the Albany Times-Union, Regeneron $REGN had already told officials last month that they were expanding their plans for manufacturing, office and lab space in Rensselaer, boosting their initial hiring plans from 1,100 to 1,500 while blueprinting an extra 300,000 square feet of space for the complex. 

image232

  By The ASCO Post
Posted: 9/13/2018 2:20:30 PM
Last Updated: 9/13/2018 5:04:27 PM 

(FDA) today approved moxetumomab pasudotox-tdfk (Lumoxiti) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) 

US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia
image233

  TARRYTOWN, N.Y. and PARIS, Sept. 15, 2018 /PRNewswire/ 

Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Sept. 15, 2018 /PRNewswire/ 

DUPIXENT is the first biologic for adult patients with uncontrolled moderate‑to‑severe atopic dermatitis.1-3

seeking biotech alpha noteworthy information 2018

Lumoxiti (moxetumomab pasudotox-tdfk)

image234

 Sep. 13, 2018 2:17 PM ET 

FDA OKs AstraZeneca's Lumoxiti for type of leukemia

US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia
image235

  September 12, 2018 

Gilead to Develop Hepatitis B Therapies Using Precision's ARCUS Genome Editing Platform

ARCUS is a next-generation genome editing platform derived from a natural genome editing enzyme called a homing endonuclease.
image236

 Sep. 19, 2018 7:18 AM ET|About: AstraZeneca Group plc (AZN)|By: , SA News Editor 

Reuters reports that AstraZeneca (NYSE:AZN) is all in in China, leveraging partnerships with tech giants Alibaba and Tencent, smart cancer diagnostics, all-in-one diabetes kits and artificial intelligence systems to improve ambulance pick-ups to become a broad healthcare provider there.

image237

  CARLSBAD, Calif., Sept. 18, 2018 /PRNewswire/ -- Thermo Fisher Scientific, Inc., the world leader in serving science, has licensed CRISPR technologies from the Broad Institute and ERS Genomics (foundational University of California IP) to bolster its genome editing intellectual property (IP) portfolio.  

image238

 April 09, 2018

Top 10 Sequencing Companies

#1. Illumina Revenues: $2.752 billion in 2017

After years of dominating high-end NGS technologies, Illumina in January announced the launch of a markedly smaller system, the one-cubic-foot iSeq 100 sequencer. At $19,900, the iSeq 100 is a bargain compared to the company’s $50,000 MiniSeq or its NovaSeq, which sells for close to $1 million—with Illumina  

Sequencing and array-based solutions for analysis of genetic variation and function, in fields ranging from cancer research to agriculture Cost-Effective Sequencing Enables Researchers to Scale Cancer Study

seeking biotech alpha september 2018 insight

image240

 BEERSE, BELGIUM, September 7, 2018 

European Commission expands labelling for Janssen’s INVOKANA® and VOKANAMET® to include positive data on cardiovascular outcomes 

INVOKANA® and INVOKAMET®/INVOKAMET® XR
image242

  September 13, 2018 9:20 AM|PR Newswire 

AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress

Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis and axial SpA.
image243

 eptember 13, 2018 at 7:00 AM EDT 

FDA TO REVIEW EYLEA® (AFLIBERCEPT) INJECTION FOR THE TREATMENT OF DIABETIC RETINOPATHY

EYLEA® (aflibercept) Injection
image244

 NORTH CHICAGO, Ill., Sept. 13, 2018 /PRNewswire/ -- AbbVie (NYSE : ABBV

AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis

Risankizumab (ABBV-066) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis and psoriatic arthritis.
image245

  Sep. 12, 2018 6:55 AM ET 

 FDA grants priority review to Merck’s sBLA for KEYTRUDA as monotherapy for treatment of locally advanced or metastatic NSCLC

KEYTRUDA® (pembrolizumab)

Contact Us

send us a comment

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

seeking biotech alpha

Moorestown, New Jersey, United States

732-232-1334